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Using a Bioabsorbable DeviceFigure 1. Percentage of Residual Shunting Diagnosed by cTTE During
Follow-up
During follow-up, contrast transthoracic echocardiography (cTTE) was used to
grade residual shunting as none, minimal, moderate, or severe. One day after
closure, a residual shunt was present in 60%: minimal in 31.7%, moderate in
20%, and severe in 8.3%. At 12-month follow-up, 25% of patients had a
residual shunt: minimal in 17.9%, moderate in 5.4%, and severe in 1.8%
(p ¼ 0.76 compared with 6-month follow-up). At 24-month follow-up, 30.9%
had a residual shunt: minimal in 21.8%, moderate in 9.1%, and severe in 0.0%
(p ¼ 0.37 compared with 12-month follow-up). A high residual shunt rate is
still present 2 years after closure using a bioabsorbable device. Long-term
follow-up seems to be necessary. IH ¼ in hospital; M ¼ months.To the Editor: A relatively high percentage of residual shunting was
present 6 months after patent foramen ovale (PFO) closure using a
bioabsorbable device (1). The presence of moderate to severe residual
shunt might increase the risk of cryptogenic stroke (2,3). Despite the
fact that the device is currently off the market, many patients were
treated worldwide, and little is known about the long-term efﬁcacy
and safety. We report the long-term safety and efﬁcacy of the bio-
absorbable device used for percutaneous PFO closure.
As reported previously, between November 2007 and January
2009, all consecutive patients who underwent a percutaneous
closure of a symptomatic PFO with a bioabsorbable device (Biostar,
NMT Medical, Boston, Massachusetts) were included (1). Intra-
cardiac echocardiography was used during most procedures.
After discharge, routine follow-up was scheduled at 1, 6, 12, and
24 months, using contrast transthoracic echocardiography (cTTE).
The residual shunt rate was classiﬁed as none, minimal, moderate,
and severe, as described previously (1).
Continuous variables with normal distribution are presented as
mean  SD. Residual shunt sizes at different time points were
compared using the Wilcoxon signed rank test. Univariate statis-
tical analysis, using a Cox proportional hazards model, was used to
identify risk factors for residual shunting and adverse events after
PFO closure. All statistical analyses were performed using SPSS
software version 17.0 (SAS Institute, Cary, North Carolina).
Percutaneous PFO closure with the bioabsorbable device was
performed in 62 consecutive patients (55% women; mean age: 47.7
 11.8 years). Ninety-four percent of the patients had experienced
a cryptogenic stroke or transient ischemic attack (TIA) and were
referred by a neurologist. Eight patients (12.9%) had a history of
supraventricular tachycardia (SVT).
These data were previously reported (1). In summary, device
implantation was successful in 60 patients (96.8%), and there were
complications in 2 patients (3.2%). A minimal vascular surgical
intervention was needed to retrieve the device at the femoral vein in
both. A small groin hematoma was present in 6 patients (9.7%).
There were no procedure-related deaths, major adverse cardiac
events, or stroke between discharge and 2-year follow-up. In 7
patients (11.3%), new SVTs were diagnosed in the ﬁrst month after
closure, and 1 (1.6%) was diagnosed between 1- and 6-month
follow-up. Patients with known rhythm disorders did not report an
increase in SVT episodes after PFO closure. A TIA recurred in 2
patients, both within the ﬁrst year after closure. No device-related
complications or recurrent ischemic cerebral events occurred be-
tween 12- and 24-month follow-up.
One day after closure, a residual shuntwas present in 60% (36 of 60
patients): minimal in 31.7%, moderate in 20%, and severe in 8.3% of
patients. At 12-month follow-up, in total, 25% of patients (14 of 56
patients) had a residual shunt: minimal in 17.9%, moderate in 5.4%,
and severe in 1.8% (p ¼ 0.76 compared with 6-month follow-up asreported previously) (1). The 4 patients missing from this follow-up
hadno residual shunt at 6months.At 24-month follow-up, 30.9%(17
of 55 patients) had a residual shunt (21.8% minimal, 9.1% moderate,
and 0.0% severe; p ¼ 0.37) compared with 12-month follow-up. At
24-month follow up, cTTE was not performed in 4 patients, and 1
patient was lost to follow-up. Three of these 4 patients were the same
as described at 12-month follow-up. The other 2 patients had no
residual shunt at 12-month follow-up. All these patients had no new
symptoms or complications at 24-month follow-up. Between 12- and
24-month follow-up, the residual shunt size remained the same in 8
patients and both increased and decreased by 1 level in 1 patient.
Three patients with a minimal residual shunt at 12-month follow-up
had no shunt at 24-month follow-up. However, 6 patients without a
shunt at 12-month follow-up experienced aminimal residual shunt at
24-month follow-up. No predictors of residual shunt could be iden-
tiﬁed. Efﬁcacy data are shown in Figure 1.
The bioabsorbable device has a high residual shunt rate of 30%,
even 2 years after closure. This implies that this device was insuf-
ﬁcient for percutaneous closure of a PFO, and long-term follow-up
seems to be necessary.
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P2Y12-Based Platelet Function
Assays Should be Complemented
With Cyclooxygenase-Dependent
Testing in Framing the
Therapeutic Windows for Dual
Antiplatelet Therapy
We read with interest the paper by Cuisset et al. (1) on the subject of
very low on-treatment platelet reactivity (VLTPR) as a measure of
hyper-response to thienopyridines. The efﬁcacy of platelet inhibition
as evaluated by vasodilator-stimulated phosphoprotein (VASP)
phosphorylation ﬂow cytometry assay was used as a predictor of non–
access site–related bleeding events. The absence of information
regarding the periprocedural use of aspirin and the related cyclo-
oxygenase-dependent platelet inhibitory response is a major drawback
of the present study (1). Dual antiplatelet therapy, capitalizing on
different pathways of platelet inhibition, has been paramount inimproving outcomes in patients with acute coronary syndromes within
both the low- and high-risk strata (2). It is unclear from the study by
Cuisset et al. (1) whether their utilization of different thienopyridine
protocols had any impact on aspirin administration or dosing. We
believe that this omission compromises the robustness of the presented
data. By disregarding the variability in the individual responsiveness to
aspirin, the authors have assumed that all patients had a similar level of
platelet inhibition before exposure to thienopyridines. By adhering to
this assumption, the authors have negated the independent contribu-
tion of aspirin response as a confounding variable in their clinical
outcomes trial. The acknowledged widespread variability in aspirin-
induced platelet inhibition may have inﬂuenced both the incidence of
ischemic and bleeding events (3,4). The cumulative effect of dual an-
tiplatelet therapy is achieved by compounding 2 different mechanisms
of anti-aggregation. It stands to reason, therefore, that strategies
designed to delineate the therapeutic window of antiplatelet therapy
need to be more comprehensive than the one presented in the current
study, which focused solely on P2Y12 platelet receptor activity. They
would need to incorporate platelet function testing exploring all drug-
speciﬁc pathways of platelet inhibition implemented in an individual
patient. This point is underscored by the very low sensitivity of the
VLTRP dichotomization threshold of the platelet reactivity index
VASP.The proposedmarker performs sufﬁciently in isolating patients
who are unlikely to suffer a bleeding event. Conversely, its sensitivity
of 17% is clearly inadequate in identifying patients who are prone to
bleeding. The authors demonstrated that patients with VLTRP did
not have a lower thrombotic adverse event rate compared with those
remaining within the targeted therapeutic window. This information
coupled with the high negative predictive value of the platelet reac-
tivity index VASP threshold is interesting and warrants further -
validation. Another issue worth looking into stems from the authors’
decision to exclude patients with a known bleeding diathesis (1).
Although the rationale for selecting a homogenous patient popula-
tion is clear, in doing so the authors have excluded high-risk patients
who are likely to gain the greatest beneﬁt from individualized anti-
platelet therapy management. The aforementioned caveats not-
withstanding, the authors are to be congratulated on highlighting the
importance of documenting interpatient variability in response to
antiplatelet therapy, which is the foundation of subsequent individual
tailoring of platelet inhibition.
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